SCHEMBL2019391

SCHEMBL2019391

Cc1cc(C)c(-c2nnc(N(C)C3CCCc4ccccc43)c3ccccc23)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
HTT P42858 2/20 0.38
XBP1 P17861 1/20 0.38
RAB9A P51151 1/20 0.37
MAPT P10636 1/20 0.36
EPHX2 P34913 1/20 0.34
SPR P35270 1/20 0.33
PER2 O15055 1/20 0.33
CRY1 Q16526 1/20 0.33
CRY2 Q49AN0 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNA4 P43681 1/20 0.33
LMNA P02545 3/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
CRHR1 P34998 1/20 0.32
HPGD P15428 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2020824 0.97 ALDH1A1 (0.35) ALDH1A1HTTXBP1RAB9AMAPT
SCHEMBL2024607 0.94 MAOA (0.38) ALDH1A1HTTXBP1MAPTSPR
SCHEMBL12574543 0.91 ALDH1A1 (0.40) ALDH1A1HTTXBP1RAB9APER2
SCHEMBL2022299 0.91 ALDH1A1 (0.40) ALDH1A1HTTXBP1RAB9APER2
SCHEMBL2017025 0.82 RAB9A (0.39) ALDH1A1HTTXBP1RAB9ASPR
SCHEMBL2018943 0.80 CRHR1 (0.34) CRHR1
SCHEMBL2019380 0.79 RAB9A (0.36) ALDH1A1HTTXBP1RAB9ASPR
SCHEMBL2014518 0.78 GBA1 (0.38) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL2019595 0.75 MAOA (0.35) RAB9ASPRPER2CRY1CRY2
SCHEMBL2015639 0.72 ALDH1A1 (0.38) ALDH1A1HTTXBP1RAB9ASPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US claimed
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US disclosed
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines MMP25, MMP9, MMP3 ALDH1A1 403/4885HTT 3469/4885XBP1 3930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.